Markets:

Overview

News

Currencies

International

Treasuries

Xenon Pharmaceuticals Inc. - Common Shares (NQ:XENE)

58.98 -0.57 (-0.96%)

Streaming Delayed Price Updated: 4:00 PM EDT, Sep 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Xenon Pharmaceuticals Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Xenon Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 08, 2022

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

Earnings Scheduled For November 8, 2022 ↗

November 08, 2022

Companies Reporting Before The Bell • Adtran (NASDAQ:ADTN) is likely to report quarterly earnings at $0.18 per share on revenue of $330.39 million.

Via Benzinga

Earnings Preview: Xenon Pharmaceuticals ↗

November 07, 2022

Xenon Pharmaceuticals (NASDAQ:XENE) is set to give its latest quarterly earnings report on Tuesday, 2022-11-08. Here's what investors need to know before the announcement. Analysts estimate that Xenon...

Via Benzinga

Xenon Pharmaceuticals Strengthens Leadership Team with Appointment of Andrea DiFabio as Chief Legal Officer and Corporate Secretary

November 07, 2022

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

Analyst Sees This Epilepsy Player As 'M&A Sweet Spot' ↗

October 19, 2022

Via Benzinga

4 Analysts Have This to Say About Xenon Pharmaceuticals ↗

October 11, 2022

Within the last quarter, Xenon Pharmaceuticals (NASDAQ:XENE) has observed the following analyst ratings:

Via Benzinga

Xenon Pharmaceuticals Announces Launch of XEN1101 Phase 3 Program with Initiation of X-TOLE2 Clinical Trial in Patients with Focal Onset Seizures

November 03, 2022

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

Hurry! 7 Pitiful Nasdaq Stocks to Sell Before 2022 Ends. ↗

November 01, 2022

As the Fed continues to tighten the market, consider putting these seven on your list of overvalued Nasdaq stocks to sell before 2022 ends.

Via InvestorPlace

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2022 Financial Results and Provide Corporate Update

November 01, 2022

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

Analyst Ratings for Xenon Pharmaceuticals ↗

August 29, 2022

Xenon Pharmaceuticals (NASDAQ:XENE) has observed the following analyst ratings within the last quarter:

Via Benzinga

4 Analysts Have This to Say About Xenon Pharmaceuticals ↗

August 11, 2022

Within the last quarter, Xenon Pharmaceuticals (NASDAQ:XENE) has observed the following analyst ratings:

Via Benzinga

Xenon's Epilepsy Candidate Rapidly Reduces Focal Onset Seizure Frequency ↗

June 23, 2022

Via Benzinga

Xenon Pharmaceuticals Shares Drop On Proposed Public Offering ↗

June 22, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2022 ↗

October 19, 2022

Upgrades

Via Benzinga

Recap: Xenon Pharmaceuticals Q1 Earnings ↗

May 10, 2022

Xenon Pharmaceuticals (NASDAQ:XENE) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Swing Trading Stock Watchlist For The Week Of Sept. 6 ↗

September 04, 2022

The overall stock market health is poor. I created a watchlist this week mainly to see how many stocks were forming quality contraction or cup-and-handle patterns. Let's take a look.

Via Talk Markets

Xenon Pharmaceuticals May Have A Blockbuster Drug In Store, BofA Says ↗

August 29, 2022

Xenon Pharmaceuticals Inc’s (NASDAQ: XENE) epilepsy candidate, XEN1101, is currently in phase III trials and “looks poised to be a blockbuster,” according to BofA Securities.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 29, 2022 ↗

August 29, 2022

Upgrades

Via Benzinga

What 4 Analyst Ratings Have To Say About Xenon Pharmaceuticals ↗

August 11, 2022

Analysts have provided the following ratings for Xenon Pharmaceuticals (NASDAQ:XENE) within the last quarter:

Via Benzinga

Xenon Pharmaceuticals: Q2 Earnings Insights ↗

August 09, 2022

Xenon Pharmaceuticals (NASDAQ:XENE) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Earnings Scheduled For August 9, 2022 ↗

August 09, 2022

Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.

Via Benzinga

Earnings Outlook For Xenon Pharmaceuticals ↗

August 08, 2022

Xenon Pharmaceuticals (NASDAQ:XENE) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here's what investors need to know before the announcement.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2022 ↗

July 21, 2022

Upgrades

Via Benzinga

The Daily Biotech Pulse: F-Star Therapeutics Buyout, Orphan Drug Tag For VBI's Brain Cancer Vaccine, Xenon's Epilepsy Candidate Shows Promise ↗

June 23, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Why Xenon Pharma Flirted With A Breakout — And Then Sacrificed It All ↗

June 23, 2022

The company had bullish results in seizure treatment. But it wasn't enough.

Via Investor's Business Daily

US Stock Futures Mixed Ahead Of Jobless Claims, Powell Testimony ↗

June 23, 2022

Pre-open movers

Via Benzinga

Recap of Tuesday's Biotech Catalysts - End of the Day Summary ↗

June 21, 2022

Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid...

Via Benzinga

Looking Into Xenon Pharmaceuticals's Return On Capital Employed ↗

June 13, 2022

According to Benzinga Pro data, during Q1, Xenon Pharmaceuticals (NASDAQ:XENE) posted sales of $8.77 million. Earnings were up 23.06%, but Xenon Pharmaceuticals still reported an overall loss of $19.67...

Via Benzinga

The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves ↗

May 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Earnings Scheduled For May 10, 2022 ↗

May 10, 2022

Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.